Gilde’s Latest Venture Fund Guided By Health Care Cost-Cutting
This article was originally published in The Pink Sheet Daily
Executive Summary
The European VC closed a €145 million ($200 million) transatlantic growth fund to capitalize on health care advancements that provide better care at lower cost.
You may also be interested in...
Abingworth Attracts $375M For Its New Bioventures Fund
The committed capital is nearly half what the 40-year-old firm raised from its previous vehicle and its sidecar in 2007–2008, but it's a huge sum compared with what most life science VCs can drum up these days.
OrbiMed’s Big Fund Signals A Potential Return To Health For VCs
The largest dedicated health care investor has closed a huge new fund, which came almost entirely from existing investors. OrbiMed isn’t the only firm capitalizing on the robust biotech IPO market. A few VCs are starting to take gains from IPO winners through secondary offerings.
Private Equity Reinvents Its Take On Biopharma
Biopharma offers the best PE returns of any health care sector, but represents only about a third of private equity investment in health care as investors remain wary of high-risk R&D and tend to focus on easier targets, which are in limited supply. As the low-hanging fruit disappears, PE investors are looking at new approaches beyond outright purchases and sorting out opportunities in emerging markets.